GB2541191A — Use of cannabinoids in the treatment of epilepsy
Assigned to GW Pharma Ltd · Expires 2017-02-15 · 9y expired
What this patent protects
Cannabidiolic acid (CBDA) for use in the treatment of epilepsy, preferably where the epilepsy is a generalised epilepsy characterised by tonic-clonic seizures. Preferably the CBDA is in the form of a highly purified extract of cannabis such that the CBDA is present at greater tha…
USPTO Abstract
Cannabidiolic acid (CBDA) for use in the treatment of epilepsy, preferably where the epilepsy is a generalised epilepsy characterised by tonic-clonic seizures. Preferably the CBDA is in the form of a highly purified extract of cannabis such that the CBDA is present at greater than 98% of the total extract (w/w) and comprises less than 1% (w/w) tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA). The CBD may be synthetically produced. The CBDA may be used with cannabidiol (CBD) preferably where the CBDA:CBD ratio is in the range from 9:1 to 1:9 (CBDA:CBD). Preferably the CBD is used at a dose of from 1mg-100mg.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.